跳至主要内容
临床试验/NCT05746247
NCT05746247
Enrolling By Invitation
不适用

Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 750 人2022年3月1日

概览

阶段
不适用
干预措施
Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
疾病 / 适应症
Familial Hypercholesterolemia
发起方
University of Pennsylvania
入组人数
750
试验地点
2
主要终点
Proportion of flagged patients diagnosed with FH (familial hypercholesterolemia) as a result of the intervention
状态
Enrolling By Invitation
最后更新
上个月

概览

简要总结

The goal of this study is to identify individuals at high risk of FH, and to encourage the appropriate diagnosis and treatment of individuals at high risk of FH through the use of implementation science and behavioral economics principles.

Phase 1: Applying the FIND FH tool to the health system EHR and gathering data for pilot development; Phase 2: Pilot development and implementation; Phase 3: Conduct a large-scale pragmatic trial consistent with recommendations and learnings from the pilots in Phase 2

详细描述

Phase 1: Aim 1: Adjusting and refining the application of the FIND FH tool to the UPHS EHR database Aim 2: Identifying the barriers and facilitators to making a diagnosis of FH and initiating or intensifying therapy for individuals with FH through qualitative interviews with clinicians and patients and creating a behavioral roadmap to inform the implementation approaches to test in the pilots Phase 2: Aim 1: Co-design implementation strategies using behavioral economics in partnership with the Family Heart Foundation Aim 2: Pilot implementation strategies with an enrollment goal of 80 patients total (40 per pilot) who have been flagged by the FIND FH tool as having probable FH to ascertain feasibility, acceptability, and appropriateness Phase 3: Conduct a large-scale pragmatic trial consistent with recommendations and learnings from the pilots in Phase 2

注册库
clinicaltrials.gov
开始日期
2022年3月1日
结束日期
2026年6月30日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Must be a patient at Penn Medicine
  • Must have been flagged by the FIND FH tool as having a high probability of FH
  • First language is English
  • Resides in PA or NJ

排除标准

  • Already have been clinically diagnosed with FH using the proper ICD-10 code
  • Currently see a lipid specialist at Penn Medicine
  • Pass study clinician's Study Validity Check

研究组 & 干预措施

Patients without a primary care physician within the UPHS health system

Patients without a primary care physician within the UPHS health system will receive direct outreach from the study team to invite them to schedule a visit with a lipid specialist for a formal evaluation of FH.

干预措施: Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation

Patients with a primary care physician within the UPHS health system

For patients with a primary care physician within the UPHS health system, their primary care physicians will be asked to review and sign physician referrals to a lipid specialist and invite patients to schedule a visit with a lipid specialist for a formal evaluation of FH.

干预措施: Testing centralized referral mechanism for PCPs

Patients with a primary care physician within the UPHS health system

For patients with a primary care physician within the UPHS health system, their primary care physicians will be asked to review and sign physician referrals to a lipid specialist and invite patients to schedule a visit with a lipid specialist for a formal evaluation of FH.

干预措施: Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation

结局指标

主要结局

Proportion of flagged patients diagnosed with FH (familial hypercholesterolemia) as a result of the intervention

时间窗: Day 1 - post intervention study visit

Patients will be evaluated for familial hypercholesterolemia (FH), an underdiagnosed genetic type of high cholesterol. An FH diagnosis will be defined using the Dutch Lipid Clinic Network Diagnostic (DLCN) Criteria for FH (Unlikely, Possible, Probable, Definite). The clinician will also make a clinical assessment of FH informed by the DLCN score and clinical expertise from the appointment.

次要结局

  • Proportion of patients that have a change to their lipid management because of the intervention(Day 1 - post intervention study visit)
  • Proportion of patients that have a change to their lipid management among patients that were candidates for a change to their lipid management because of the intervention(Day 1 - post intervention study visit)

研究点 (2)

Loading locations...

相似试验